DANCANN PHARMA A/S: Financial statements 2022
CVR: 39426005
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
DANCANN PHARMA A/S (CVR 39426005) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -7,575,000 and a net result of DKK -16,064,000 compared with DKK -11,750,000 the year before. Equity in the 2022 report amounted to DKK 62,793,000. The solvency ratio was 85.7%. The company had 10 employees in the financial year.
- Revenue
- DKK 0
- Gross Profit
- DKK -7,575,000
- Profit/Loss
- DKK -16,064,000
- Equity
- DKK 62,793,000
- Total Assets
- DKK 73,276,000
- Employees
- 10
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 0 | -7.6 mio. | -16.1 mio. | 62.8 mio. | 10 |
| 2021 | 0 | -6.8 mio. | -11.8 mio. | 53.4 mio. | 10 |
| 2020 | - | -4.8 mio. | -4.3 mio. | 44.3 mio. | 4 |
| 2019 | - | -422 t. | -1.2 mio. | -1.4 mio. | 4 |
Official annual report
Keep an eye on DANCANN PHARMA A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of September 20, 2022, Jeppe Krog Rasmussen has joined the board of directors of DANCANN PHARMA A/S.
As of September 20, 2022, Alexander Schoeneck has joined the board of directors of DANCANN PHARMA A/S.
As of September 20, 2022, Magnus Østergaard Dahlmann has left the board of directors of DANCANN PHARMA A/S.
As of September 20, 2022, Per Wester has left the board of directors of DANCANN PHARMA A/S.
DANCANN PHARMA A/S has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK -11,750,000.
As of April 27, 2022, Christian Carlsen has joined the board of directors of DANCANN PHARMA A/S.
As of April 27, 2022, Tue Østergaard has joined the board of directors of DANCANN PHARMA A/S.
As of April 27, 2022, Jeppe Krog Rasmussen has left the board of directors of DANCANN PHARMA A/S.
As of April 26, 2022, Christian Carlsen has left the board of directors of DANCANN PHARMA A/S.
About DANCANN PHARMA A/S
DANCANN PHARMA A/S is a Danish company of the type Aktieselskab based in Ansager, founded in 2018. The company is under bankruptcy. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named DANCANN PHARMA ApS and DANCANN PHARMA IVS. The company is owned by JEQ Capital AB. The company has 1 employee (2026). In 2024, the company reported a gross profit of DKK -148,000 and a net result of DKK -8,346,000 compared with DKK -62,260,000 the year before. Equity in the 2024 report amounted to DKK 14,620,000.